Mitesh Lotia, MD

Mitesh Lotia , MD

Medical Director and Neurologist

Neuroscience

Mitesh Lotia

Overview

Mitesh Lotia, M.D. is a fellowship trained Movement Disorder Neurologist with an impressive educational and training background. After completing a two-year Movement Disorders Fellowship at Baylor College of Medicine under the guidance of Dr. Joseph Jankovic, where he also served as a chief fellow, Dr. Lotia joined the University of Arkansas for Medical Sciences (UAMS) as an Assistant Professor. At UAMS, Dr. Lotia served as the neurology residency Program Director and worked in multiple leadership roles.

He is widely published and an accomplished speaker. Dr. Lotia joins AdventhHealth Neuroscience Institute as a Medical Director for Movement Disorders, helping patients with Parkinson’s disease, Dystonia, Tourette syndrome and other movement disorders.

Dr. Lotia is a recipient of A.B.Baker Teacher Recognition Award, founding member of Functional Neurological Disorder Society (FNDS), and an active member of American Academy of Neurology (AAN) and Movement Disorders Society (MDS).

Articles

Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson's disease

SCIENTIFIC REPORTS

2022

Trends in Demographics of Neurology House Staff in the United States

CUREUS JOURNAL OF MEDICAL SCIENCE

2021

Utility of objective gait measures in levodopa-unresponsive freezing in Parkinson's

CLINICAL CASE REPORTS

2021

COVID-19 and stroke, a case series and review of literature.

Brain, behavior, & immunity - health

2020

Resident Education During COVID-19 Pandemic: Effectiveness of Virtual Electroencephalogram Learning

CUREUS JOURNAL OF MEDICAL SCIENCE

2020

Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN)

MOLECULAR GENETICS & GENOMIC MEDICINE

2019

Clinical Reasoning: A 65-year-old man with asymmetric weakness and paresthesias.

Neurology

2019

Leg stereotypy syndrome: phenomenology and prevalence

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

2018

Botulinum Toxin for the Treatment of Tremor and Tics

SEMINARS IN NEUROLOGY

2016

New and emerging medical therapies in Parkinson's disease

Expert opinion on pharmacotherapy

2016

More Publication Information

Education & Training

Education

Terna Medical College & Hospital

Residency

Stroke Neurology at Washington Hospital Center

Neurology at University of Louisville School of Medicine

Fellowship

Neurological Disorder at Baylor College of Medicine

Board Certifications

The American Board of Psychiatry and Neurology

Associated Clinical Trials

NCT05924243

A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON’S DISEASE

Icon for trial | BP43176 A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON&rsqu

This study is currently enrolling.

The purpose of this study is to investigate what happens to RO7486967 once it is in the body, what RO7486967 does to the body, and to compare the effects (good or bad) of RO7486967 versus placebo on the inflammation in the brai ...

NCT05766813

“A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson’s Disease”

Icon for trial | ITI-214-202 “A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson’s Disease”

This study is currently enrolling.

The purpose of this clinical research study is to look at an investigational study drug called lenrispodun. The study will investigate if lenrispodun can help to increase the time of good control of movement symptoms, that is, ...